GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » Price-to-Owner-Earnings

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Price-to-Owner-Earnings : (As of Jun. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-05), Y-mAbs Therapeutics's share price is $12.02. Y-mAbs Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Y-mAbs Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


YMAB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.78
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-05), Y-mAbs Therapeutics's share price is $12.02. Y-mAbs Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.49. Therefore, Y-mAbs Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-05), Y-mAbs Therapeutics's share price is $12.02. Y-mAbs Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.49. Therefore, Y-mAbs Therapeutics's PE Ratio without NRI for today is At Loss.


Y-mAbs Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Y-mAbs Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics Price-to-Owner-Earnings Chart

Y-mAbs Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Y-mAbs Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Y-mAbs Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Y-mAbs Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Y-mAbs Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Y-mAbs Therapeutics's Price-to-Owner-Earnings falls into.



Y-mAbs Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Y-mAbs Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=12.02/-0.72
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Y-mAbs Therapeutics  (NAS:YMAB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Y-mAbs Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
230 Park Avenue, Suite 3350, New York, NY, USA, 10169
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Executives
Thomas Gad director, officer: President and Chairman C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Biotech Aps Wg 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Johan Wedell-wedellsborg director, 10 percent owner RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Michael J Rossi director, officer: President & CEO 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Vignesh Rajah officer: SVP and CMO HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Bo Kruse director, officer: EVP, CFO, Secy & Treas. C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Susan Laura Smith officer: Senior Vice President, CCO 5 OVERLOOK CT, LAMBERTVILLE NJ 08530
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus director, officer: Chief Executive Officer C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed officer: Sr. VP and CSO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman officer: Sr. VP and CCO C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gregory S Raskin director C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169

Y-mAbs Therapeutics (Y-mAbs Therapeutics) Headlines

From GuruFocus

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

By sperokesalga sperokesalga 05-26-2023